

1° if the member practises within a limited liability partnership:

- a) the partnership contract and amendments;
- b) the declaration of registration of the partnership and any update;
- c) the up-to-date register of the partners;
- d) where applicable, the up-to-date register of the managers;
- e) the names and home addresses of the partnership's principal officers;

2° if he practises within a joint-stock company:

- a) the up-to-date register of the articles and by-laws of the joint-stock company;
- b) the declaration of registration of the joint-stock company and any update;
- c) the up-to-date register of the securities of the joint-stock company;
- d) any shareholders' agreement and voting agreement and amendments;
- e) the up-to-date register of the directors of the joint-stock company;
- f) the names and home addresses of the company's principal officers.

On a general partnership being continued as a limited liability partnership or a joint-stock company or limited liability partnership being constituted, a member must, on the date of the occurrence, send a notice to his or her clients informing them of the nature and effects of the change of status of the partnership or joint-stock company, in particular with respect to his professional liability and that of the partnership or joint-stock company.

## CHAPTER VI TRANSITIONAL AND FINAL

**13.** A member who practises within a joint-stock company constituted before coming into force of this Regulation must comply with this Regulation not later than one year following that date.

**14.** Until the Order has received a permission from the competent authority for the professional liability insurance Fund of the Order to provide a security against liability that a partnership or joint-stock company may incur as a result of fault by the member in the course of his professional activities within a partnership or joint-stock company, the member must provide and maintain, for this partnership or joint-stock company, by means of an insurance or suretyship contract, such a guarantee in accordance with the requirements set out in section 10 of this Regulation.

**15.** This Regulation shall come into force on the fifteenth day following the date of publication in the *Gazette officielle du Québec*.

1500

### Draft Regulation

Medical Act  
(R.S.Q., c. M-9)

Professional Code  
(R.S.Q., c. C-26)

### Physicians — Activities contemplated in section 31 of the Medical Act which may be engaged in by classes of persons other than physicians — Amendment

Notice is hereby given, in accordance with sections 10 and 11 of the Regulations Act (R.S.Q., c. R-18.1), that the "Regulation amending the Regulation respecting the activities contemplated in section 31 of the Medical Act which may be engaged in by classes of persons other than physicians", adopted by the Board of directors of the Collège des médecins du Québec, may be submitted to the Government, which may approve it with or without amendment, upon the expiry of 45 days following this publication.

The purpose of this Regulation is to update the "Regulation respecting the activities contemplated in section 31 of the Medical Act which may be engaged in by classes of persons other than physicians" by authorizing, to the specialized nurse practitioner in primary care, to prescribe new diagnostic techniques and new medical treatments and by replacing the schedule of medications which he or she is authorized to prescribe.

The draft Regulation has no impact on enterprises, including small and medium-sized businesses.

Further information may be obtained by contacting, Mtre Linda Bélanger, Legal Advisor, Collège des médecins du Québec, 2170, boulevard René-Lévesque Ouest, Montréal (Québec) H3H 2T8; telephone number: 514 933-4441, extension 5362 or 1 888 633-3246; facsimile number: 514 933-5374, e-mail: lbelanger@cmq.org

Any person having comments to make is asked to transmit them, before the expiry of the 45-day period, to the Chair of the Office des professions du Québec, 800, place D'Youville, 10<sup>e</sup> étage, Québec (Québec) G1R 5Z3. Those comments will be forwarded by the Office to the Minister of Justice; they may be also forwarded to the professional order that made the Regulation as well as to the persons, departments and agencies concerned.

JEAN PAUL DUTRISAC,  
*Chair of the Office des  
professions du Québec*

### **Regulation amending the Regulation respecting the activities contemplated in section 31 of the Medical Act which may be engaged in by classes of persons other than physicians**

Medical Act

(R.S.Q., c. M-9, s. 19, (1), par. *b*)

**1.** The Regulation respecting the activities contemplated in section 31 of the Medical Act which may be engaged in by classes of persons other than physicians (R.R.Q., c. M-9, r.13) is amended, in paragraph (2) of section 8.4, by adding, after subparagraph *d* the following:

“*e*) puncture of olecranon bursa;”

**2.** This regulation is amended by adding, in paragraph (4) of section 8.4 after subparagraph *i*, the following:

“*j*) immobilization of a limb using an open plaster or fibreglass brace in the absence of fracture, for a short term;”

**3.** This regulation is amended by adding, in paragraph (5) of section 8.4 after subparagraph *c*, the following:

“*d*) partial onychectomy;

“*e*) removal of superficial cutaneous lesions:

- molluscum pendulum or contagiosum;
- keratosis with a scalpel;
- small lipoma ≤ 1 cm;

“*f*) install an IUD, except in a nulliparous woman;

“*g*) remove an IUD.”

**4.** This regulation is amended by replacing the section 9 by the following:

“**9.** A specialized nurse practitioner candidate or a person who for the purposes of the recognition of an equivalence of diplomas or education must complete a training period or training contemplated in the Regulation respecting Ordre des infirmières et infirmiers du Québec classes of specialties related to the performance of certain acts contemplated in section 36.1 of the Nurses Act (R.S.Q., c. I-8, r. 8) may perform an activity stipulated in section 5.

Besides the terms and conditions stipulated in subdivisions 2 and 2.1, a specialized nurse practitioner candidate or a person who for the purposes of the recognition of an equivalence of diplomas and education must complete a training period or training performs this activity under the following terms and conditions:

(1) the activity is performed in a training site indicated on a training card issued pursuant to the Regulation respecting Ordre des infirmières et infirmiers du Québec classes of specialties related to the performance of acts contemplated in section 36.1 of the Nurses Act under the supervision of a medical specialist of the specialty contemplated or of a family physician as appropriate, with the collaboration of a specialized nurse practitioner or, failing that, a nurse who has at least 3 years of relevant clinical experience;

(2) the activity is performed insofar as it is required to complete the program in which he or she is enrolled and, when the latter is completed, during the period in which he or she is eligible for the examination prescribed for that speciality as contemplated in Division III of this Regulation or, to complete a training period or training, as the case may be, for the purposes of the recognition of an equivalence of diplomas and education.”

**5.** Schedule I to this regulation is amended by:

(1) in paragraph (5) of section 1, after “toes” adding “• heel bone (calcaneum)”;

(2) in paragraph (1) of section 2, after “ultrasonography of the breast as part of an abnormal screening mammogram” by adding “• ultrasonography of the breast of a woman who is nursing, a woman who is pregnant, a woman less than thirty years old presenting a palpable mass in her breast”;

(3) in subparagraph *b* of paragraph (1) of section 4, after “purulent discharge” adding “skin or nail mycosis”;

(4) in paragraph (2) of section 4, after “amylase” adding “• prostatic specific antigen (PSA), • apo-lipoprotein B (Apo-B)”, after “bilirubin, direct and total” adding “• calcium” and at the end of “•βhCG (quantitative),” adding “• magnesium”;

(5) in paragraph (6) of section 4, after “alpha-fetoprotein, estradiol” adding “trisomy 21”;

(6) at the end, adding the following paragraph:

“(7) pathology  
• superficial cutaneous lesions”.

**6.** This regulation is amended by the replacement of Schedule II by the following:

«**SCHEDULE II**  
(s. 8.4, subpar. 3)

**LIST OF CLASSES OF MEDICATIONS NURSE PRACTITIONERS SPECIALIZED IN PRIMARY CARE MAY PRESCRIBE WITH OR WITHOUT RESTRICTION**

This list is based on the classification used by the Régie de l'assurance maladie du Québec to establish the list of medications.

**Specifications**

**P** Can be prescribed, renewed or stopped unless there is a limit indicated.

**R** Can be prescribed according to the original dose to maintain treatment, provided that the medication in question has already been prescribed for the patient by the partner physician (renewal). Maximum duration of 12 months. Cannot be ceased.

**A** Can be prescribed as dose adjustment provided that the drug in question had been prescribed for the patient by the partner physician and the physician has established a medical treatment plan (as part of joint follow-up). Cannot be ceased.

**Specifications**

<b>4 : 00</b>	<b>Antihistamine Drugs</b>	P	
<b>8 : 00</b>	<b>Anti-infective Agents</b>		
8 : 08	Mebendazole	P	(orally only)

8 : 12.06	Cephalosporins	P	(orally only)
	Ceftriaxone sodium	P	(IM single dose only)
8 : 12.12	Macrolides	P	(orally only)
8 : 12.16	Penicillins	P	(orally only)
8 : 12.18	Quinolones	P	(orally only) (14 days or less)
8 : 12.20	Sulfonamides	R	(orally only)
	Trimethoprim/ Sulfamethoxazole	P	(orally only)
8 : 12.24	Tetracyclines	P	(orally only)
8 : 12.28	Antibacterials, Miscellaneous		
	Clindamycin	P	(orally only)
	Erythromycine/ Acetylsulfisoxazol	P	(pediatrics only)
8 : 14.08	Fluconazol	P	(orally only) (single dose only)
8 : 14.28	Nystatin	P	(orally only)
8 : 16.04	Antituberculosis Agents	R	(orally only)
8 : 18.04	Adamantanes	P	(orally only) (7 days or less)
8 : 18.32	Nucleosides and Nucleotides	P	(orally only) (10 days or less)
8 : 30.08	Antimalarials	P	(orally only) (for prevention)
8 : 30.92	Metronidazol	P	(orally only)
8 : 36	Urinary anti-infectives	P	(orally only)
<b>10 : 00</b>	<b>Antineoplastic Agents</b>		
	Methotrexate as Antirhumatismal Agent	R	
	Tamoxifen	R	
<b>12 : 00</b>	<b>Autonomic Drugs</b>		
12 : 08.08	Antimuscarinic / Anticholinergic		
	Ipratropium (Bromide)	R	(aerosol)
	Tiotropium (Bromide monohydrate)	R	(aerosol)

12 : 12.08	Beta-Adrenergic Agonists			24 : 08.16	Central Alpha-adrenergic agonists	R and A
	Formoterol	R and A	(inhalator)	24 : 08.20	Direct Vasodilators	R and A
	Salbutamol (sulfate)	P and R	(14 days or less for 1 treatment) (including expired prescription)	24 : 12.08	Nitrates and Nitrites	R
	Salmeterol	R and A	(inhalator)	24 : 12.92	Vasodilating Agents, Miscellaneous	R
	Terbutaline	P and R	(14 days or less for 1 treatment) (including expired prescription)	24 : 20	Alpha - adrenergic Blocking Agents	R and A
12 : 12.12	Alpha and beta - Adrenergic Agonists			24 : 24	Beta - adrenergic Blocking Agents	R and A
	Epinephrin (chlorhydrate)	P	(in an emergency)	24 : 28.08	Dihydropyridines	R and A
	Epinephrin	R	(auto-injector)	24 : 28.92	Calcium-Channel Blocking Agents, Miscellaneous	R and A
12 : 16.04	Alpha-adrenergic Blocking Agents			24 : 32.04	Angiotensin-Converting Enzyme Inhibitors (A.C.E.I.)	R and A
	Alfuzosin (chlorhydrate)	R		24 : 32.08	Angiotensin II Receptor Antagonists	R and A
	Dihydroergotamine (mesylate)	R		24 : 32.20	Aldosterone Receptor Antagonists	R
	Tamsulosin (chlorhydrate)	R		<b>28 : 00</b>	<b>Central Nervous System Agents</b>	
12 : 20.04	Cyclobenzaprine (chlorhydrate)	P	(7 days)	28 : 08.04	Nonsteroidal Anti-inflammatory Agents	P and R (14 days or less) (once)
12 : 92	Drugs A.N.S., miscellenous			28 : 08.08	Codeine	P (12 tablets only)
	Nicotine	P		28 : 08.92	Acetaminophen	P
	Varenicline (tartrate)	P		28 : 12.04	Phenobarbital	R (epilepsy)
<b>20 : 00</b>	<b>Blood Formation, Coagulation and Thrombosis</b>			28 : 12.08	Benzodiazepines (Clobazam and Clonazepam)	R (epilepsy)
20 : 04.04	Iron Preparations	P	(orally only) (for 1 month)	28 : 12.12	Hydantoins	R
20 : 12.04	Anticoagulants	R and A	(orally only)	28 : 12.92	Anticonvulsants, Miscellaneous	R
<b>24 : 00</b>	<b>Cardiovascular Drugs</b>			28 : 16.04	Antidepressants	R
24 : 04.08	Cardiotonic Agents	R		28 : 16.08	Antipsychotics	R
24 : 06.04	Bile Acid Sequestrants	R		28 : 20.4	Amphetamines	
24 : 06.06	Fibric Acid Derivatives	R			Dexamphetamine (Sulfate)	R
24 : 06.08	HMG-CoA Reductase Inhibitors	R and A		28 : 20.92	Other stimulants C.N.S.	
24 : 06.92	Niacin	R			Methylphenidate(hydrochloride)	R
				28 : 24.08	Benzodiazepines Lorazepam	R P (12 tablets only)

28 : 24.92	Hydroxyzine (hydrochloride)	P		
28 : 28	Lithium	R		
28 : 32.28	Agonists of 5-HT-1 Receptor	R		
28 : 36.92	Antiparkinsonian Agents	R		
28 : 92	Central Nervous System Agents, Miscellaneous	R		
<b>36 : 00</b>	<b>Diagnostic Agents</b>			
36 : 26	Diabetes Mellitus			
	Quantitative Blood Ketone Reagent	P		
	Quantitative Blood Glucose Reagent	P		
36 : 88	Urinalysis	P		
<b>40 : 00</b>	<b>Électrolytic, Caloric, and Water Balance</b>			
40 : 12	Replacement Preparations	P		
40 : 28	Diuretics	R and A		
40 : 28.16	Potassium-sparing Diuretics	R		
40 : 36	Irrigating Solutions	P		
<b>48 : 00</b>	<b>Antitussives, expectorants and mucolytic agents</b>			
48 : 24	Mucolytic Agents	R		
<b>52 : 00</b>	<b>Eye, Ear, Nose, and Throat (EENT) Preparations</b>			
52 : 02	E.E.N.T. Antiallergic Agents Sodium Cromoglicate	P		
52 : 04.04	Antibacterial except : Chloramphenicol Gentamicin Tobramycin	P		
52 : 08.08	E.E.N.T. Corticosteroids except : Ophthalmic Pomade, Solution and Suspension	P		
52 : 16	Local Anesthetics	P		
52 : 92	EENT Drugs, Miscellaneous			
	Ipratropium (Bromide)	P		
	Sodium (Chloride)	P		
<b>56 : 00</b>	<b>Gastrointestinal Drugs</b>			
56 : 04	Antiacids-adsorbents	P		
56 : 16	Digestants Lactase	P		
56 : 22.92	Antiemetics, Miscellaneous			
	Doxylamine / pyridoxine	P		
56 : 28.12	Histamine H <sub>2</sub> -Antagonists			
	Famotidine	R		
	Ranitidine	P		
56 : 28.28	Prostaglandins Misoprostol	R		
56 : 28.32	Protectants Sucralfate	P		(for breastfeeding only)
56 : 28.36	Proton-pump Inhibitors	P		(30 days or less)
56 : 32	Prokinetic Agents Domperidone	P		(for breastfeeding only)
<b>68 : 00</b>	<b>Hormones and Synthetic Substitutes</b>			
68 : 04	Corticosteroids	P		(Aerosol only) (28 days or less)
	Prednisone	P		(orally for asthma and COPD) (10 days maximum)
68 : 12	Contraceptives	P		
68 : 16.04	Estrogens	R and A		
68 : 16.12	Estrogen Agonists – antagonists	R		
68 : 20.02	Alpha-glucosidase Inhibitors	R and A		
68 : 20.04	Biguanides	R and A		
68 : 20.08	Insulins	R and A		
68 : 20.20	Sulfonylureas except : Chlorpropamid	R and A		
68 : 22.12	Glycogenolytic Agents	R		
68 : 24	Parathyroid	R		
68 : 28	Desmopressin (DDAVP)	R		
68 : 32	Progestins except : Depot Medroxyprogesterone Acetate	R and A		
		P		(injectable)

68 : 36.04	Thyroid Agents except : Liothyronine Sodium	R and A	
<b>84 : 00</b>	<b>Skin and Mucous Membrane Agents</b>		
84 : 04.04	Antibacterials	P	
84 : 04.08	Antifungals	P	
84 : 04.12	Scabicides and pediculicides	P	
84 : 04.92	Local anti-infective, Miscellaneous	P	
<b>84 : 06</b>	<b>Anti-inflammatory Agents</b>	P	(medium and low strength)
84 : 28	Keratolytic Agents	P	
84 : 32	Keratoplastic Agents	R	
84 : 92	Skin and Mucous Membrane Agents, Miscellaneous except : Fluorouracil	P	
<b>86 : 00</b>	<b>Smooth Muscle Relaxants</b>		
86 : 12	Genitourinary Smooth Muscle Relaxants	R	
86 : 16	Respiratory Smooth Muscle Relaxants		
	Aminophyllin	R	
	Theophyllin	R	
<b>88 : 00</b>	<b>Vitamins</b>		
88 : 08	Vitamin B Complex except : Cyanocobalamin	P R	(orally only) (including injectable)
88 : 16	Vitamine D	P	(orally only)
88 : 28	Multivitamin Preparations A, D and C	P	(orally only)
<b>92 : 00</b>	<b>Miscellaneous Therapeutic Agents</b>		
92 : 00.02	Miscellaneous, Others	R	
92 : 08	5 – Alpha-reductase Inhibitors		
	Finasteride	R	
92 : 16	Antigout agents	R	
92 : 24	Inhibitors of bone resorption		
	Alendronate monosodium	R	
	Etidronate disodium	R	
	Ridedronate sodium	R	

**Non RAMQ formulary medication****Local /Topical Anesthetic Agents**

Topical Lidocaine-prilocain	P	(stamps, pomade)
Lidocaine Hydrochloride with or without epinephrine, injectable	P	(local infiltration)
Tetracaine Hydrochloride	P	(ophthalmic solution)
Intravenous Solutions	P	
Zanamivir	P	
Oseltamivir	P	
Zopiclone	P	
Metformin hydrochloride	R and A	
Neomycin, sulfate-polymyxin B sulfate-hydrocortisone	P	(otic solution, 7 days)
Ciprofloxacin, chlorhydrate of hydrocortisone	P	(otic solution, 7 days)

**EXCEPTION DRUGS**

	<b>Generic Name</b>	<b>Specifications</b>
1.	Amphetamine (Mixed salts of)	R
2.	Atomoxetine (Hydrochloride)	R
3.	Betahistine (Dihydrochloride)	R
4.	Bisacodyl	P
5.	Donepezil	R and A
6.	Estradiol	R and A (skin patch)
7.	Formoterol (fumarate dihydrate) /budesonide	R and A
8.	Galantamine (hydrobromide)	R and A
9.	Gliclazide	R and A
10.	Glimepiride	R and A
11.	Mineral oil	P
12.	Insulin detemir	R and A
13.	Insulin glargine	R and A
14.	Magnesium (hydroxide)	P

15.	Memantine (hydrochloride)	R and A	34.	Repaglinide	R and A
16.	Methylphenidate (hydrochloride)	R	35.	Rivastigmine	R and A (orally and patch)
17.	Metronidazole	P (vaginal gel)	36.	Salmeterol / Fluticasone	R and A
18.	Absorbent dressing – sodium chloride	P	37.	Saxagliptin	R and A
19.	Absorbent dressing – fiber gelling	P	38.	Senosides A and B	P
20.	Absorbent Dressing – hydrophilic foam alone or in association	P	39.	Sitagliptin	R and A
21.	Absorbent dressing border – fiber gelling	P	40.	Sitagliptin / Metformin	R and A
22.	Absorbent dressing border – rayon and polyester fibers	P	41.	Tolterodine	R
23.	Absorbent dressing border – hydrophilic foam alone or in association	P	42.	Tretinoine	P
24.	Anti-odor dressing – activated charcoal	P	<p><b>7.</b> This regulation comes into force fifteen days after the date of its publication in the <i>Gazette Officielle du Québec</i>.</p>		
25.	Antimicrobial dressing – iodized	P	1504		
26.	Antimicrobial dressing border – silver	P			
27.	Moisture absorption dressing – hydrocolloid or polyurethane	P			
28.	Moisture absorption dressing border – hydrocolloid or polyurethane	P			
29.	Low adherent wound contact layer dressing – polyamide or silicone	P			
30.	Monobasic sodium phosphate / dibasic sodium phosphate	P			
31.	Pioglitazone (Hydrochloride)	R and A			
32.	Micronized progesterone	R			
33.	Quantitative reagent for measuring prothrombin time in blood	P			